In prostate cancer, reliable markers of disease status are important for selecting and monitoring treatment. Two recent studies have shown that increased levels of circulating cells predict worse ...

Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria. Targeting ...

Comparison of circulating tumor cell numbers before and after treatment is predictive for overall survival in patients with metastatic castration-resistant prostate cancer; this comparison is more ...

Circulating tumor cells (CTCs), originating from primary neoplastic tissues, infiltrate blood vessels, migrate through the bloodstream, and establish secondary tumor foci. The detection of CTCs ...

Among patients with hormone-sensitive prostate cancer, circulating tumor cell (CTC) count at the start of treatment may be able to indicate which patients are likely to live longer after treatment, as ...

Abstract Number: SESS-1071 (Spotlight Poster) Title: Overall survival results of Bria-IMT™ allogenic whole cell-based cancer vaccine Time: Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, ...

This innovative vaccine, known as BNT116 and developed by BioNTech, is designed to combat non-small cell lung cancer ...

cancer vaccine that targets KRAS-mutant tumors, at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland. ELI-002 was evaluated in individuals with mutant KRAS-driven colorectal or pancreatic ...